| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Astragaloside A targets multiple pathways, including the PI3K/Akt pathway, through which it regulates HIF-1α and angiogenesis. It has been studied for its potential anti-inflammatory, anti-tumor, and anti-aging effects, indicating its interaction with various cellular targets. Its diverse pharmacological effects are attributed to its modulation of multiple signaling pathways.
|
|---|---|
| ln Vitro |
Astragaloside IV improves post-ischemic heart function and ameliorated reperfusion arrhythmias accompanied by a significant increase in myocardial antioxidative enzyme superoxide dismutase activity in rat hearts in vitro. While, Astragaloside IVs protective effect on heart function can be partially abrogated by the nitric oxide synthase inhibitor, Nomega-nitro-L-arginine methyl ester.
Kinase Assay: AS-IV treatment also activates JAK2/STAT3 and ERK1/2 signaling pathways, and up-regulates endothelial nitric oxide synthase (eNOS) expression and nitric oxide (NO) production Cell Assay: Astragaloside IV (2-40 μM) dose-dependently decreased TGF-β-induced a-SMA, fibronectin, CTGF, collagen I and III expression, up-regulated Smad7, but decreased p-Smad2 and p-Smad3 expression in NRK-49F cells [2]. Moreover, Astragaloside IV prevented tubular epithelial apoptosis partially through inhibiting MAPK pathway activity, thereby ameliorating renal fibrosis. In vitro, Astragaloside A improves post-ischemic cardiac function and reduces reperfusion arrhythmias in a rat heart model. These effects are accompanied by an increase in myocardial antioxidant enzyme superoxide dismutase activity. In HUVECs, it regulates HIF-1α and angiogenesis through the PI3K/Akt pathway. |
| ln Vivo |
Astragaloside IV significantly reduces infarct size in dogs subjected to coronary ligation in vivo. Astragaloside IV attenuates isoproterenol-induced subendocardial necrosis, serum lactate dehydrogenase and creatine kinase activation, and lipid oxide product malondialdehyde formation in rats. It also reduces sarcoplasmic reticulum Ca(2+)-uptake ability and Ca(2+)-ATPase (SERCA2a) activity as well as SERCA2a mRNA expression in myocardial injury rats. |
| Enzyme Assay |
In vitro enzyme or receptor binding studies would involve assessing the compound's effect on specific targets like PI3K or its downstream signaling components. For example, its ability to modulate the PI3K/Akt pathway can be measured by Western blotting for phosphorylated Akt.
|
| Cell Assay |
Cells such as HUVECs are treated with Astragaloside A, and its effects on HIF-1α expression and angiogenesis are measured. Other cellular models are used to study its anti-inflammatory, anti-tumor, or anti-aging activities. These assays help to elucidate the compound's mechanism of action.
|
| Animal Protocol |
5 and 10 mg/kg; 3.33, 10, and 33 mg/kg, intraperitoneal injection Astragaloside IV (5 and 10 mg/kg/day, intraperitoneal injection) reduced serum lactate dehydrogenase and creatine kinase enzyme levels and attenuated this reduction in the Ca2+-ATPase activity in rats. Astragaloside IV (3.33, 10, and 33 mg/kg, intraperitoneal injection) treatment attenuated renal damage and improved renal function through inhibiting TGF-β/Smad signaling pathway in a dose-dependent manner in unilateral ureteral obstruction kidneys. |
| ADME/Pharmacokinetics |
Pharmacokinetic studies would investigate the absorption, distribution, metabolism, and excretion (ADME) of Astragaloside A. As a natural saponin, its oral bioavailability and systemic exposure are key parameters. Studies have shown that astragaloside A is metabolized to cycloastragenol.
|
| Toxicity/Toxicokinetics |
Toxicology studies would assess the safety of Astragaloside A. As a natural compound from a traditional herb, its safety profile is generally considered favorable, but systematic toxicological evaluation is necessary.
|
| References |
Planta Med.2006 Jan;72(1):4-8;Eur J Pharmacol.2007 Jul 30;568(1-3):203-12.
|
| Additional Infomation |
It has been reported that Astragalus membranaceus, Astragalus mongholicus, and Astragalus membranaceus contain Cyclosiversioside F, and relevant data are available for reference.
Astragaloside A is a well-known bioactive compound from traditional Chinese medicine. It is used as a research tool to study various pharmacological effects, including cardiovascular protection, immunomodulation, and anti-aging. It is also known as Astragaloside IV. |
| Molecular Formula |
C41H68O14
|
|
|---|---|---|
| Molecular Weight |
784.97
|
|
| Exact Mass |
784.46
|
|
| CAS # |
83207-58-3
|
|
| Related CAS # |
|
|
| PubChem CID |
13943299
|
|
| Appearance |
Typically exists as solid at room temperature
|
|
| Density |
1.4±0.1 g/cm3
|
|
| Boiling Point |
895.7±65.0 °C at 760 mmHg
|
|
| Melting Point |
284-286ºC
|
|
| Flash Point |
495.5±34.3 °C
|
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
|
| Index of Refraction |
1.621
|
|
| LogP |
1.96
|
|
| Hydrogen Bond Donor Count |
9
|
|
| Hydrogen Bond Acceptor Count |
14
|
|
| Rotatable Bond Count |
7
|
|
| Heavy Atom Count |
55
|
|
| Complexity |
1460
|
|
| Defined Atom Stereocenter Count |
21
|
|
| SMILES |
C[C@@]12C[C@H](O)[C@H]([C@@]3(CC[C@H](C(O)(C)C)O3)C)[C@@]1(C)CC[C@@]13C[C@]41CC[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C(C)(C)[C@@H]4[C@H](C[C@@H]23)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
|
|
| InChi Key |
QMNWISYXSJWHRY-AUJDEUPOSA-N
|
|
| InChi Code |
O[C@H]1[C@H](O)[C@@H](CO)O[C@](O[C@H]2C[C@]([C@@](C[C@H](O)[C@]3([H])[C@@]4(C)O[C@@H](C(C)(O)C)CC4)(C)[C@]3(C)CC5)([H])[C@]56[C@]7(C6)[C@]2([H])C(C)(C)[C@@H](O[C@]8([H])OC[C@@H](O)[C@H](O)[C@H]8O)CC7)([H])[C@@H]1O
|
|
| Chemical Name |
(2R,3R,4S,5S,6R)-2-[[(1S,3R,6S,8R,9S,11S,12S,14S,15R,16R)-14-hydroxy-15-[(2S,5R)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-9-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2739 mL | 6.3697 mL | 12.7393 mL | |
| 5 mM | 0.2548 mL | 1.2739 mL | 2.5479 mL | |
| 10 mM | 0.1274 mL | 0.6370 mL | 1.2739 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA